Disposition of Foscarnet during Peritoneal Dialysis
| Autor: | Adam Akers, Francesca T. Aweeka, Donald S. Fraley, Gary R. Matzke, Alicia C. M. Alexander |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Foscarnet medicine.medical_specialty medicine.medical_treatment Urology 030204 cardiovascular system & hematology 030226 pharmacology & pharmacy Peritoneal dialysis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Peritoneal Dialysis Continuous Ambulatory Pharmacokinetics medicine Humans Pharmacology (medical) Creatinine Chemotherapy business.industry Continuous ambulatory peritoneal dialysis virus diseases Acute Kidney Injury Surgery chemistry Cytomegalovirus Infections Hemodialysis Complication business Peritoneal Dialysis Half-Life medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 30:1106-1109 |
| ISSN: | 1542-6270 1060-0280 |
| Popis: | OBJECTIVE: To report the disposition of foscarnet in a patient undergoing peritoneal dialysis. CASE SUMMARY: A 34-year-old man with AIDS received foscarnet for the treatment of esophageal cytomegalovirus. We characterized the clearance of foscarnet in this patient during continuous cyclic peritoneal dialysis (CCPD) and continuous ambulatory peritoneal dialysis (CAPD). DISCUSSION: The foscarnet half-lives during CCPD and CAPD were 41.4 and 45.8 hours, respectively. These values are significantly greater than the half-life of 4.5 hours observed in patients with normal renal function and about half that reported in anuric patients undergoing hemodialysis during the interdialytic period. The CCPD and CAPD clearances of foscarnet were 5.8 and 4.5 mL/min, respectively; the CAPD clearances of creatinine and urea nitrogen were 4.1 and 6.0 mL/min, respectively. The patient's estimated total body clearance values of foscarnet during CCPD and CAPD were 9.8 and 8.8 mL/min, respectively. Thus, CCPD and CAPD augmented the patient's residual clearance of foscarnet by 145% and 105%, respectively. CONCLUSIONS: Since incremental increases in residual clearance of 30% or more generally will result in clinically significant changes in a drug's serum concentration, foscarnet dosage needs to be individualized for patients receiving peritoneal dialysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|